Your Flagship Gene Therapy Event
Engage in high-impact discussions, uncover emerging trends, and position yourself among the key players shaping the future of gene therapy.
This is your chance to learn directly from industry leaders at Astellas Pharmaceuticals, Apertura Gene Therapy, Bayer, and more, as they share how they’re optimizing vector design, improving delivery to extra-hepatic targets, and tackling redosing to prioritise safety, efficacy, and commercial viability for gene therapies.
Walk away with a strengthened network to build collaborations and insights to tackle key challenges that will strengthen your gene therapy pipeline from the start to the end. Whether you’re building a brand-new product, or scaling an existing program, this is the only industry-led gene therapy forum focussed on accelerating gene therapy development for companies at every stage.
The Sessions Everyone’s Talking About
Commercial Insights & Investment Panel
Gain actionable guidance on securing the right investors, shaping development to meet payer and patient expectations, and building a pipeline positioned for long-term success in rare and ultra-rare diseases.
Hear from:
- Lianna Orlando, Vice President of Research & Partner, CureDuchenne Ventures
- Lindsay Marjoram, Director of Research, Barth Syndrome Foundation
- Jon Weber, Senior Director, Cell & Gene Therapy Market Access Lead, Bayer
Advance Precision & Safety in Gene Therapy with Next-Generation Manufacturing
Explore cutting-edge capsid engineering and manufacturing strategies that improve tissue targeting and unlock therapeutic potential across complex indications, while keeping costs down to maximize ROI.
Insights from:
- Adrian Veres, Co-Founder & Chief Scientific Officer, Dyno Therapeutics
- Jorge Santiago-Oritz, Vice President, CMC & Regulatory Affairs, Apertura Gene Therapy
- Pushpendra Singh, Senior Director, Head of Product Development, Ocugen
Design Smarter, More Streamlined Trials for Rare Diseases to Maximize ROI
Learn how to optimize trial design using external controls and natural history data to accelerate timelines, whilst balancing the need to meet regulatory requirements for approval.
Lessons from:
- Stephen Poor, Head of Translational Medicine, Apellis Pharmaceuticals
- Amber Salzman, Chief Executive Officer, Epicrispr Biotechnologies
- Mitra Tavakkoli, Executive Medical Lead, BridgeBio Gene Therapy
Unlock New Market Opportunities by Bringing Gene Therapy to High-Prevalence Diseases
Discover scalable strategies for manufacturing, pricing, and reimbursement that enable commercial success while driving access for indications with larger patient populations.
- Damir Simic, Executive Director, Astellas Pharmaceuticals
- Derek Jackson, Senior Vice President, Product Development, Pacira BioSciences
- Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics
What Set Us Apart in 2026?
Understanding the Evolving Investment Landscape
With funding continuing to be a key challenge for gene therapy innovators, the 2026 program hones in on what’s shaping investor confidence, the creative financing models emerging beyond traditional VC routes, and how early strategic planning can set the foundation for long-term commercial success and patient access.
Navigating Regulation & Overcoming Setbacks
As the regulatory landscape for gene therapy continues to evolve, 2026 brings exclusive insights from the MHRA on expanding into the UK to maximize commercial potential. Attendees will also hear from industry leaders who have successfully navigated setbacks sharing lessons learned and practical guidance to maintain momentum on the path to approval and commercialization.
Data-Driven Presentations on the Expansion into Common Diseases
Our Common Disease Focus Day has developed since last year, and with more and more companies expanding into larger indications, this time we are bringing you case studies and data-led presentations – as well as the strategic brainstorms you loved last year. Across a range of indications from ophthalmic to osteoarthritic, you’ll gain first-hand insights into clinical progress, trial design evolution, and commercial positioning strategies that are paving the way for gene therapies to deliver impact at scale.
What to Expect
- 100+ World-leading Gene Therapy Experts
- 3 Days of Cutting-Edge Strategic & Technical Sessions
- Meaningful Networking to Drive Critical Industry Connections
- Your Definitive Industry-Led Forum Focused Exclusively on Advancing Gene Therapies
- CEO & Investor Panel Discussion to Drive Clinical & Commercial Success
Attending Companies Include
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.